DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 8.4% in January

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 191,900 shares, a decline of 8.4% from the January 15th total of 209,500 shares. Based on an average trading volume of 103,200 shares, the short-interest ratio is presently 1.9 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

DiaMedica Therapeutics Trading Down 2.1 %

Shares of DMAC stock traded down $0.13 on Tuesday, reaching $6.16. The company had a trading volume of 66,713 shares, compared to its average volume of 75,381. The company has a 50-day moving average of $5.70 and a 200-day moving average of $4.77. DiaMedica Therapeutics has a 12 month low of $2.14 and a 12 month high of $6.45. The stock has a market cap of $263.40 million, a PE ratio of -11.00 and a beta of 1.46.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several large investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp acquired a new position in shares of DiaMedica Therapeutics in the 4th quarter valued at $122,000. Millennium Management LLC lifted its holdings in DiaMedica Therapeutics by 151.8% during the fourth quarter. Millennium Management LLC now owns 84,829 shares of the company’s stock worth $461,000 after acquiring an additional 51,139 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in DiaMedica Therapeutics in the fourth quarter valued at about $79,000. 683 Capital Management LLC bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter worth about $413,000. Finally, Jane Street Group LLC acquired a new stake in shares of DiaMedica Therapeutics during the fourth quarter worth about $229,000. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.